The post Robert Mueller Can’t Testify Before Congress Due To Parkinson’s: Report appeared on BitcoinEthereumNews.com. Topline Robert Mueller, the former FBI director and Justice Department special counsel who investigated Russian interference in the 2016 election, has been diagnosed with Parkinson’s disease, the New York Times reported on Sunday, which will prevent him from testifying before the House Oversight Committee as part of its Jeffrey Epstein probe. Special Counsel Robert Mueller makes a statement about the Russia investigation at the Justice Department in Washington, DC. Getty Images Key Facts Citing a statement from Mueller’s family, the Times reported that he was diagnosed with Parkinson’s disease in “the summer of 2021” and he has “retired from the practice of law at the end of that year.” As a result of the neurological condition, the former FBI director has been facing mobility and speech issues, the report added, citing “people familiar with his condition.” The GOP-led House Oversight Committee had subpoenaed the former special counsel and wanted to question him about the FBI’s handling of its investigation into the disgraced financier and convicted sex offender Jeffrey Epstein during Mueller’s time as the agency’s director. Due to Mueller’s diagnosis, the committee has withdrawn its request for Mueller’s testimony this week. Crucial Quote ABC News confirmed the House committee’s decision to withdraw the subpoena. A spokesperson told the outlet: “We’ve learned that Mr. Mueller has health issues that preclude him from being able to testify.” What Do We Know About The Subpoena Issued To Mueller? In a letter sent to Mueller last month, House Oversight Committee Chair James Comer wrote: “It is imperative that Congress conduct oversight of the federal government’s enforcement of sex trafficking laws generally and specifically its handling of the investigation and prosecution of Mr. Epstein and Ms. [Ghislaine] Maxwell…Because you were FBI Director during the time when Mr. Epstein was under investigation by the FBI, the… The post Robert Mueller Can’t Testify Before Congress Due To Parkinson’s: Report appeared on BitcoinEthereumNews.com. Topline Robert Mueller, the former FBI director and Justice Department special counsel who investigated Russian interference in the 2016 election, has been diagnosed with Parkinson’s disease, the New York Times reported on Sunday, which will prevent him from testifying before the House Oversight Committee as part of its Jeffrey Epstein probe. Special Counsel Robert Mueller makes a statement about the Russia investigation at the Justice Department in Washington, DC. Getty Images Key Facts Citing a statement from Mueller’s family, the Times reported that he was diagnosed with Parkinson’s disease in “the summer of 2021” and he has “retired from the practice of law at the end of that year.” As a result of the neurological condition, the former FBI director has been facing mobility and speech issues, the report added, citing “people familiar with his condition.” The GOP-led House Oversight Committee had subpoenaed the former special counsel and wanted to question him about the FBI’s handling of its investigation into the disgraced financier and convicted sex offender Jeffrey Epstein during Mueller’s time as the agency’s director. Due to Mueller’s diagnosis, the committee has withdrawn its request for Mueller’s testimony this week. Crucial Quote ABC News confirmed the House committee’s decision to withdraw the subpoena. A spokesperson told the outlet: “We’ve learned that Mr. Mueller has health issues that preclude him from being able to testify.” What Do We Know About The Subpoena Issued To Mueller? In a letter sent to Mueller last month, House Oversight Committee Chair James Comer wrote: “It is imperative that Congress conduct oversight of the federal government’s enforcement of sex trafficking laws generally and specifically its handling of the investigation and prosecution of Mr. Epstein and Ms. [Ghislaine] Maxwell…Because you were FBI Director during the time when Mr. Epstein was under investigation by the FBI, the…

Robert Mueller Can’t Testify Before Congress Due To Parkinson’s: Report

Topline

Robert Mueller, the former FBI director and Justice Department special counsel who investigated Russian interference in the 2016 election, has been diagnosed with Parkinson’s disease, the New York Times reported on Sunday, which will prevent him from testifying before the House Oversight Committee as part of its Jeffrey Epstein probe.

Special Counsel Robert Mueller makes a statement about the Russia investigation at the Justice Department in Washington, DC.

Getty Images

Key Facts

Citing a statement from Mueller’s family, the Times reported that he was diagnosed with Parkinson’s disease in “the summer of 2021” and he has “retired from the practice of law at the end of that year.”

As a result of the neurological condition, the former FBI director has been facing mobility and speech issues, the report added, citing “people familiar with his condition.”

The GOP-led House Oversight Committee had subpoenaed the former special counsel and wanted to question him about the FBI’s handling of its investigation into the disgraced financier and convicted sex offender Jeffrey Epstein during Mueller’s time as the agency’s director.

Due to Mueller’s diagnosis, the committee has withdrawn its request for Mueller’s testimony this week.

Crucial Quote

ABC News confirmed the House committee’s decision to withdraw the subpoena. A spokesperson told the outlet: “We’ve learned that Mr. Mueller has health issues that preclude him from being able to testify.”

What Do We Know About The Subpoena Issued To Mueller?

In a letter sent to Mueller last month, House Oversight Committee Chair James Comer wrote: “It is imperative that Congress conduct oversight of the federal government’s enforcement of sex trafficking laws generally and specifically its handling of the investigation and prosecution of Mr. Epstein and Ms. [Ghislaine] Maxwell…Because you were FBI Director during the time when Mr. Epstein was under investigation by the FBI, the Committee believes that you possess knowledge and information relevant to its investigation.”

Source: https://www.forbes.com/sites/siladityaray/2025/09/01/robert-muellers-has-parkinsons-and-cant-testify-before-congress-report-says/

Market Opportunity
Sex Token Logo
Sex Token Price(SEX)
$47,499.51
$47,499.51$47,499.51
-7.42%
USD
Sex Token (SEX) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23